TP53 hot spot mutations in ovarian cancer: Selective resistance to microtubule stabilizers in vitro and differential survival outcomes from the Cancer Genome Atlas

Gynecologic Oncology

Volumn 138, Issue 1, 2015, Pages 159-164

  Seagle, Brandon Luke L ^a   Yang, Chia Ping Huang ^b   Eng, Kevin H ^c   Dandapani, Monica ^a   Odunsi Akanji, Oluwatosin ^a   Goldberg, Gary L ^b   Odunsi, Kunle ^c   Horwitz, Susan Band ^b   Shahabi, Shohreh ^d  

^a Western Connecticut Health Network   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Drug therapy; Ovarian neoplasms; Survival; TP53 genes

Indexed keywords

EPOTHILONE B; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; IXABEPILONE; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; PROTEIN BAX; PROTEIN MDM2; PROTEIN P21; PROTEIN P53; EPOTHILONE DERIVATIVE; TP53 PROTEIN, HUMAN; TUBULIN MODULATOR;

ADJUVANT THERAPY; APOPTOSIS; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER PATIENT; CANCER RESISTANCE; CANCER SURVIVAL; CARCINOMA CELL; CELL GROWTH; CELL LYSATE; CHEMOSENSITIVITY; CODON; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; CYTOTOXICITY ASSAY; ELECTROPHORETIC MOBILITY; EXOME; FEMALE; GENE DOSAGE; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN CELL; IN VITRO STUDY; MICROTUBULE; MITOSIS INHIBITION; OVARY CARCINOMA; OVERALL SURVIVAL; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN ACETYLATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; SOMATIC MUTATION; WESTERN BLOTTING; CELL DEATH; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; MIDDLE AGED; MUTATION; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

CELL DEATH; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; EPOTHILONES; FEMALE; GENES, P53; HUMANS; MIDDLE AGED; MUTATION; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PACLITAXEL; TUBULIN MODULATORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84931560283     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2015.04.039     Document Type: Article

References (39)

1. American Cancer Society http://www.Cancer.Org/Cancer/Ovariancancer/Detailedguide/Index (accessed August, 2014)
2. National Comprehensive Cancer Network NCCN clinical practice guidelines in oncology Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer 2014 (Version 1.2014)
3. C. Kandoth, M.D. McLellan, F. Vandin, K. Ye, B. Niu, and C. Lu Mutational landscape and significance across 12 major cancer types Nature 502 2013 333 339
4. Cancer Genome Atlas Research Network Integrated genomic analyses of ovarian carcinoma Nature 474 2011 609 615
5. P.A.J. Muller, and K.H. Vousdan Mutant p53 in cancer: new functions and therapeutic opportunities Cancer Cell 25 2014 304 317
6. P. Brachova, K.W. Thiel, and K.W. Leslie The consequence of oncomorphic TP53 mutations in ovarian cancer Int. J. Mol. Sci. 14 2013 19257 19275
7. S. Skeijfer, T.K. Le, S. de Jong, H. Timmer-Bosscha, S. Withoff, and N.H. Mulder Combined cytotoxic effects of tumor necrosis factor-alpha with various cytotoxic agents in tumor cell lines that are drug resistant due to mutated p53 J. Immunother. 22 1999 48 53
8. D.M. Bollag, P.A. McQueney, J. Zhu, O. Hensens, L. Koupal, and J. Liesch Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action Cancer Res. 55 1995 2325 2333
9. D. Donovan, and L.T. Vahdat Epothilones: clinical update and future directions Oncology (Williston Park) 22 2008 408 416
10. R.J. Kowalski, P. Giannakakou, and E. Hamel Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel J. Biol. Chem. 272 1997 2534 2541
11. M. Harrison, and C. Swanton Epothilones and new analogues of the microtubule modulators in taxane-resistant disease Expert Opin. Investig. Drugs 17 2008 523 546
12. M.N. Fornier Ixabepilone, first in a new class of antineoplastic agents: the natural epothilones and their analogues Clin. Breast Cancer 7 2007 757 763
13. S. Goodin Ixabepilone: a novel microtubule-stabilizing agent for the treatment of metastatic breast cancer Am. J. Health Syst. Pharm. 65 2008 2017 2026
14. H.M. McDaid, S. Mani, H.J. Shen, F. Muggia, D. Sonnichsen, and S.B. Horwitz Validation of the pharmacodynamics of BMS-247550, an analogue of epothilone B, during a phase I clinical study Clin. Cancer Res. 8 2002 2035 2043
15. J. Gao, B.A. Aksoy, U. Dogrusoz, G. Dresdner, B. Gross, and S.O. Sumer Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal Sci. Signal. 6 2013 pl1
16. E. Cerami, J. Gao, U. Dogrusoz, B.E. Gross, S.O. Sumer, and B.A. Aksoy The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data Cancer Discov. 2 2012 401 404
17. R Core Team R: A Language and Environment for Statistical Computing 2014 R Foundation for Statistical Computing Vienna, Austria (http://www.R-project.org)
18. R. Therneau A package for survival analysis in S. R package version 2.37-7 http://CRAN.R-project.org/package=survival 2014
19. L. He, C.P.H. Yang, and S.B. Horwitz Mutations in β-tubulin map to domains involved in regulation of microtubule stability in epothilone-resistant cell lines Mol. Cancer Ther. 1 2001 3 10
20. C.P.H. Yang, and S.B. Horwitz Taxol mediates serine phosphorylation of the 66-kDa Shc isoform Cancer Res. 60 2000 5171 5178
21. P. Skehan, R. Storeng, D. Scudiero, A. Monks, J. McMahon, and D. Vistica New colorimetric cytotoxicity assay for anticancer-drug screening J. Natl. Cancer Inst. 82 1990 1107 1112
22. P. Giannakakou, R. Robey, T. Fojo, and M. Blagosklonny Low concentrations of paclitaxel induce cell type-dependent p53, p21 and G1/G2 arrest instead of mitotic arrest: molecular determinants of paclitaxel-induced cytotoxicity Oncogene 20 2001 3806 3813
23. K. Torres, and S.B. Horwitz Mechanisms of taxol-induced cell death are concentration dependent Cancer Res. 58 1998 3620 3626
24. P.J. Duriez, and G.M. Shah Cleavage of poly(ADP-ribose) polymerase: a sensitive parameter to study cell death Biochem. Cell Biol. 75 1997 337 349
25. G. Blandino, A.J. Levine, and M. Oren Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy Oncogene 88 1999 477 485
26. F.L. Chang, and M.D. Lai Various forms of mutant p53 confer sensitivity to cisplatin and doxorubicin in bladder cancer cells J. Urol. 166 2001 304 310
27. Z. Duan, K.A. Brakora, and M.V. Seiden Inhibition of ABCB1 (MDMR1) and ABCB4 (MDR3) expression by small interfering RNA and reversal of paclitaxel resistance in human ovarian cancer cells Mol. Cancer Ther. 3 2004 833 838
28. J.F. Shi, N. Yang, H.J. Ding, J.H. Zhang, M.L. Hu, and Y. Leng ERalpha directly activated MDR1 transcription to increase paclitaxel-resistance of ERalpha-positive breast cancer cells in vitro and in vivo Int. J. Biochem. Cell Biol. 53 2014 35 45
29. R. Mirzayans, B. Andrias, A. Scott, and D. Murray New insights into p53 signaling and cancer cell response to DNA damage: implications for cancer therapy J. Biomed. Biotechnol. 2012 2012 170325
30. K.T. Chan, and M.L. Lung Mutant p53 expression enhances drug resistance in a hepatocellular carcinoma cell line Cancer Chemother. Pharmacol. 53 2004 519 526
31. P. Brachova, S.R. Meuting, M.J. Carlson, M.J. Goodheart, A.M. Button, and S.L. Mott TP53 oncomorphic mutations predict resistance to platinum- and taxane-based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma Int. J. Oncol. 46 2015 607 608
32. X. Meng, L.L. Laidler, E.A. Kosmacek, S. Yang, Z. Xiong, and D. Zhu Induction of mitotic cell death by overriding G2/M checkpoint in endometrial cancer cells with non-functional p53 Gynecol. Oncol. 128 2012 461 469
33. S.R. Grossman, and R.A. Frum Mechanisms of mutant p53 stabilization in cancer Subcell. Biochem. 85 2014 187 197
34. R.E. Tamura, J.F. de Vasconcellos, D. Sarkar, T.A. Libermann, P.B. Fisher, and L.F. Zerbini GADD45 proteins: central players in tumorigenesis Curr. Mol. Med. 12 2012 634 651
35. R.M. Kortlever, P.J. Higgins, and R. Bernards Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence Nat. Cell Biol. 8 2006 877 884
36. L. Havrilesky, K.M. Darcy, H. Hamdan, R.L. Priore, J. Leon, and J. Bell Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: a Gynecologic Oncology Group study J. Clin. Oncol. 21 2003 3814 3825
37. A. Reles, W.H. Wen, A. Schmider, C. Gee, I.B. Runnebaum, and U. Kilian Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer Clin. Cancer Res. 7 2001 2884 2897
38. R. Brown, J. Paul, and J. Hall Critical evaluation of p53 as a prognostic marker in ovarian cancer Expert Rev. Mol. Med. 6 2004 1 20
39. H.J. Kang, S.M. Chun, K.R. Kim, I. Sohn, and C.O. Sung Clinical relevance of gain-of-function mutations of p53 in high-grade serous ovarian carcinoma PLoS ONE 8 2013 e72609